ReviewMolecular and cellular biochemistry2024
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy.
Review in Molecular and cellular biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- A prognostic senescence-related long non-coding RNA signature identifies cold and hot tumors of stomach adenocarcinoma.Oncology letters · 2026Article
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
- Reduced Expression of LINC01515 Suppresses Proliferation and Invasion of Lung Adenocarcinoma Cells via Modulation of the miR-33a-5p/HMGA2 Signaling Axis.Current medicinal chemistry · 2026Article
- Regulatory roles of LncRNAs in colorectal cancer immune evasion: current concepts and future perspectives.Discover oncology · 2025Review
- AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.Molecular genetics and genomics : MGG · 2025Article
- Development of a mitochondrial permeability transition-driven necrosis-linked lncRNA signature for forecasting prognosis and treatment of lung adenocarcinoma.Translational cancer research · 2025Article
- The epigenetic regulatory network of long noncoding RNAs in hepatocellular carcinoma.Genes & diseases · 2025Review
- GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population.International journal of molecular sciences · 2025Article
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- A novel cancer-associated lncRNA, LINC01123, participates in tumor progression, metabolism, immune escape, and resistance.Frontiers in immunology · 2025Review
- lncSLERT Promotes Liver Metastasis in Colorectal Cancer by Down-Regulating HUNK Expression via RBM15-Mediated m6A Modification.OncoTargets and therapy · 2025Article
- OTUD6B-AS1: a multifaceted regulator of cancer with critical clinical implications.American journal of cancer research · 2025Review
- The Emerging Role of Long Non-coding RNA 01296 in Human Malignancies.Current molecular medicine · 2025Review
- Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy.Frontiers in immunology · 2025Review
- A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: Implications for biomarker discovery and therapeutic targeting.Frontiers in pharmacology · 2025Article
- Long noncoding RNAs in ubiquitination, protein degradation, and human diseases.Biochimica et biophysica acta. Gene regulatory mechanisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health concern with high mortality rates mainly due to late diagnosis and poor prognosis. Long non-coding RNAs (lncRNAs) are emerging as key regulators of gene expression in human cancer, functioning through various mechanisms including as competing endogenous RNAs (ceRNAs) and indirectly regulating miRNA expression. LncRNAs have been found to have both oncogenic and tumor-suppressive roles in cancer, with the former promoting cancer cell proliferation, migration, invasion, and poor prognosis. Recent research has shown that lncRNAs are expressed in various immune cells and are involved in cancer cell immune escape and the modulation of the tumor microenvironment, thus highlighting their potential as targets for cancer immunotherapy. Targeting lncRNAs in cancer or immune cells could enhance the anti-tumor immune response and improve cancer immunotherapy outcomes. However, further research is required to fully understand the functional roles of lncRNAs in cancer and the immune system and their potential as targets for cancer immunotherapy. This review offers a comprehensive examination of the multifaceted roles of lncRNAs in human cancers, with a focus on their potential as targets for cancer immunotherapy. By exploring the intricate mechanisms underlying lncRNA-mediated regulation of cancer cell proliferation, invasion, and immune evasion, we provide insights into the diverse therapeutic applications of these molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.